The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Microbial factories for recombinant pharmaceuticals
Open accessAbstract
Most of the hosts used to produce the 151 recombinant pharmaceuticals so far approved for human use by the Food and Drug Administration (FDA) and/or by the European Medicines Agency (EMEA) are microbial cells, either bacteria or yeast. This fact indicates that despite the diverse bottlenecks and obstacles that microbial systems pose to the efficient production of functional mammalian proteins, namely lack or unconventional post-translational modifications, proteolytic instability, poor solubility and activation of cell stress responses, among others, they represent convenient and powerful tools for recombinant protein production. The entering into the market of a progressively increasing number of protein drugs produced in non-microbial systems has not impaired the development of products obtained in microbial cells, proving the robustness of the microbial set of cellular systems (so far Escherichia coli and Saccharomyces cerevisae) developed for protein drug production. We summarize here the nature, properties and applications of all those pharmaceuticals and the relevant features of the current and potential producing hosts, in a comparative way.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Strategies for efficient production of heterologous proteins in Escherichia coli
Jana, S., & Deb, J. K. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-004-1814-0 · Cited by 349
RetractedStrategies for achieving high-level expression of genes in Escherichia coli
Makrides, S. C. (1996) · Microbiological Reviews · doi:10.1128/mmbr.60.3.512-538.1996 · Cited by 1,276
Stability of Protein Pharmaceuticals
Manning, M. C., Patel, K., & Borchardt, R. T. (1989) · Pharmaceutical Research · doi:10.1023/a:1015929109894 · Cited by 1,078
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Protein production and purification
Structural Genomics Consortium, Biologiques, A. E. F. D. M., Berkeley Structural Genomics Center, China Structural Genomics Consortium, Integrated Center for Structure and Function Innovation, Israel Structural Proteomics Center, Joint Center for Structural Genomics, Midwest Center for Structural Genomics, New York Structural GenomiX Research Center for Structural Genomics, Northeast Structural Genomics Consortium, et al. (2008) · Nature Methods · doi:10.1038/nmeth.f.202 · Cited by 916
Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli
Sørensen, H. P., & Mortensen, K. K. (2005) · Microbial Cell Factories · doi:10.1186/1475-2859-4-1 · Cited by 841 · cited 1×
“By adjusting media composition, growth temperature, inducer concentration, promoter strength and plasmid copy number, variable amounts of the target protein can be forced to appear in the soluble form [26,27], although unfortunately, many eukaryotic proteins are exclusively found trapped in IBs and seem to be resistan…”
The purification of eukaryotic polypeptides synthesized in Escherichia coli
Marston, F. A. (1986) · Biochemical Journal · doi:10.1042/bj2400001 · Cited by 836
N-Linked Glycosylation in Campylobacter jejuni and Its Functional Transfer into E. coli
Wacker, M., Linton, D., Hitchen, P. G., Nita-Lazar, M., Haslam, S. M., North, S. J., Panico, M., Morris, H. R., Dell, A., Wren, B. W., et al. (2002) · Science · doi:10.1126/science.298.5599.1790 · Cited by 777
High-yield production of a human therapeutic protein in tobacco chloroplasts
Staub, J. M., Garcia, B., Graves, J., Hajdukiewicz, P. T. J., Hunter, P., Nehra, N., Paradkar, V., Schlittler, M., Carroll, J. A., Spatola, L., et al. (2000) · Nature Biotechnology · doi:10.1038/73796 · Cited by 486
Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins
Sinclair, A. M., & Elliott, S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20319 · Cited by 461
Advances in the production of human therapeutic proteins in yeasts and filamentous fungi
Gerngross, T. U. (2004) · Nature Biotechnology · doi:10.1038/nbt1028 · Cited by 409
Recombinant expression systems in the pharmaceutical industry
Schmidt, F. R. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-004-1656-9 · Cited by 379
PEG-modified biopharmaceuticals
Bailon, P., & Won, C.-Y. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802650568 · Cited by 366
Genetic engineering of filamentous fungi — Progress, obstacles and future trends
Meyer, V. (2008) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.12.001 · Cited by 358
Recombinant Protein Production in Yeasts
Mattanovich, D., Branduardi, P., Dato, L., Gasser, B., Sauer, M., & Porro, D. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-433-9_17 · Cited by 357
Protein aggregation in recombinant bacteria: biological role of inclusion bodies
Villaverde, A., & Mar Carrió, M. (2003) · Biotechnology Letters · doi:10.1023/a:1025024104862 · Cited by 345
Self-citationGasser, B., Saloheimo, M., Rinas, U., Dragosits, M., Rodríguez-Carmona, E., Baumann, K., Giuliani, M., Parrilli, E., Branduardi, P., Lang, C., et al. (2008) · Microbial Cell Factories · doi:10.1186/1475-2859-7-11 · Cited by 326
Self-citationGarcía-Fruitós, E., González-Montalbán, N., Morell, M., Vera, A., Ferraz, R. M., Arís, A., Ventura, S., & Villaverde, A. (2005) · Microbial Cell Factories · doi:10.1186/1475-2859-4-27 · Cited by 319
Self-citationVallejo, L. F., & Rinas, U. (2004) · Microbial Cell Factories · doi:10.1186/1475-2859-3-11 · Cited by 311
Degradation of Abnormal Proteins in Escherichia coli
Goldberg, A. L. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.2.422 · Cited by 297
Stress in recombinant protein producing yeasts
Mattanovich, D., Gasser, B., Hohenblum, H., & Sauer, M. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.04.035 · Cited by 264
Retraction Note: Strategies for efficient production of heterologous proteins in Escherichia coli
Jana, S., & Deb, J. K. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5822-4 · Cited by 212
Engineering of Pichia pastoris for improved production of antibody fragments
Gasser, B., Maurer, M., Gach, J., Kunert, R., & Mattanovich, D. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20851 · Cited by 202
Recombinant Protein Production in Yeasts
Porro, D., Sauer, M., Branduardi, P., & Mattanovich, D. (2005) · Molecular Biotechnology · doi:10.1385/mb:31:3:245 · Cited by 179
Hollister, J. R., & Jarvis, D. L. (2001) · Glycobiology · doi:10.1093/glycob/11.1.1 · Cited by 163
The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi
Joosten, V., Lokman, C., van den Hondel, C. A. M. J. J., & Punt, P. J. (2003) · Microbial Cell Factories · doi:10.1186/1475-2859-2-1 · Cited by 159
Hollister, J. R., Grabenhorst, E., Nimtz, M., Conradt, H. S., & Jarvis, D. L. (2002) · Biochemistry · doi:10.1021/bi026455d · Cited by 154
Prouty, W. F., Karnovsky, M. J., & Goldberg, A. L. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41897-8 · Cited by 151
Historical Development of Monoclonal Antibody Therapeutics
Nissim, A., & Chernajovsky, Y. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_1 · Cited by 136
Novel insights into the unfolded protein response using Pichia pastoris specific DNA microarrays
Graf, A. B., Gasser, B., Dragosits, M., Sauer, M., Leparc, G., Tüchler, T., Kreil, D. P., & Mattanovich, D. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-390 · Cited by 131
Recombinant protein solubility—does more mean better?
González‐Montalbán, N., García‐Fruitós, E., & Villaverde, A. (2007) · Nature Biotechnology · doi:10.1038/nbt0707-718 · Cited by 130
Self-citationde Marco, A. (2007) · Nature Protocols · doi:10.1038/nprot.2007.400 · Cited by 126
A transgenic insect cell line engineered to produce CMP-sialic acid and sialylated glycoproteins
Aumiller, J. J., Hollister, J. R., & Jarvis, D. L. (2003) · Glycobiology · doi:10.1093/glycob/cwg051 · Cited by 112
Modifications of therapeutic proteins: challenges and prospects
Jenkins, N. (2007) · Cytotechnology · doi:10.1007/s10616-007-9075-2 · Cited by 109
Yuen, C., Storring, P. L., Tiplady, R. J., Izquierdo, M., Wait, R., Gee, C. K., Gerson, P., Lloyd, P., & Cremata, J. A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04307.x · Cited by 106
Localization of Functional Polypeptides in Bacterial Inclusion Bodies
García‐Fruitós, E., Arı́s, A., & Villaverde, A. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.01952-06 · Cited by 105
Self-citationAssessment of cell engineering strategies for improved therapeutic protein production in CHO cells
Mohan, C., Kim, Y., Koo, J., & Lee, G. M. (2008) · Biotechnology Journal · doi:10.1002/biot.200700249 · Cited by 102 · cited 1×
“In addition, recombinant products can be secreted into the chemical defined media, which simplifies both upstream and downstream purification process [ 51 ].”
BackgroundGurramkonda, C., Adnan, A., Gäbel, T., Lünsdorf, H., Roß, A., Nemani, S. K., Swaminathan, S., Khanna, N., & Rinas, U. (2009) · Microbial Cell Factories · doi:10.1186/1475-2859-8-13 · Cited by 99
Production systems for recombinant antibodies
Schirrmann, T., Al-Halabi, L., Dübel, S., & Hust, M. (2008) · Frontiers in bioscience · doi:10.2741/3024 · Cited by 91
Antibody production with yeasts and filamentous fungi: on the road to large scale?
Gasser, B., & Mattanovich, D. (2006) · Biotechnology Letters · doi:10.1007/s10529-006-9237-x · Cited by 86
Liao, Y., Jeng, J., Wang, C., Wang, S., & Chang, S. (2004) · Protein Science · doi:10.1110/ps.04679104 · Cited by 81
Learning about protein solubility from bacterial inclusion bodies
Martínez‐Alonso, M., González‐Montalbán, N., García‐Fruitós, E., & Villaverde, A. (2009) · Microbial Cell Factories · doi:10.1186/1475-2859-8-4 · Cited by 80
Self-citationSingh, S., Gras, A., Fiez-Vandal, C., Ruprecht, J. J., Rana, R. R., Martínez, M., Strange, P. G., Wagner, R., & Byrne, B. (2008) · Microbial Cell Factories · doi:10.1186/1475-2859-7-28 · Cited by 53
Parrilli, E., Vizio, D. D., Cirulli, C., & Tutino, M. L. (2008) · Microbial Cell Factories · doi:10.1186/1475-2859-7-2 · Cited by 45
Synthesis of the Human Insulin Gene: Protein Expression, Scaling Up and Bioactivity
Redwan, E. M. M. M., Matar, S. M., Abdelaziz, G., & Serour, E. A. (2007) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826060701774312 · Cited by 45
Cumulative updating of approved biopharmaceuticals
Redwan, E. M. M. M. (2008) · Human Antibodies · doi:10.3233/hab-2007-163-408 · Cited by 35
Metabolically Engineered Yeasts: ‘Potential’ Industrial Applications
Branduardi, P., Smeraldi, C., & Porro, D. (2008) · Microbial Physiology · doi:10.1159/000111990 · Cited by 35
de Marco, A. (2008) · Microbial Cell Factories · doi:10.1186/1475-2859-7-20 · Cited by 27
Human insulin receives FDA approval.
(1982) · PubMed · Cited by 25
Protein Inclusion Bodies in Recombinant Bacteria
Neubauer, P. B., Fahnert, B., Lilie, H., & Villaverde, A. (2006) · Springer eBooks · doi:10.1007/3-540-33774-1_9 · Cited by 20
Self-citation
Cited by
Microbial lipases and their industrial applications: a comprehensive review
Chandra, P., Enespa, Singh, R., & Arora, P. K. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01428-8 · Cited by 887
Adaptive laboratory evolution—Principles and applications for biotechnology
Dragosits, M., & Mattanovich, D. (2013) · Microbial Cell Factories · doi:10.1186/1475-2859-12-64 · Cited by 827
Tripathi, N. K., & Shrivastava, A. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00420 · Cited by 575
A Review of the Microbial Production of Bioactive Natural Products and Biologics
Pham, J. V., Yilma, M. A., Feliz, A., Majid, M. T., Maffetone, N., Walker, J. R., Kim, E., Cho, H. J., Reynolds, J. M., Song, M. C., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01404 · Cited by 565
Costa, S., Almeida, A., Castro, A., & Domingues, L. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00063 · Cited by 450
Metadata
- Authors
- Ferrer-Miralles, N., Domingo-Espín, J., Corchero, J. L., Vázquez, E., & Villaverde, A.
- Venue
- Microbial Cell Factories
- Published
- 2009-03-24
- Volume
- 8
- Issue
- 1
- Pages
- 17-17
- ISSN
- 1475-2859 (ISSN-L)
- OpenAlex
- W2129217817
- Cited by
- 465
- References
- 50
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.